CGEN · Compugen Ltd · Insider Trading
Trades by corporate insiders — officers, directors and holders of more than 10% of the shares — disclosed to the SEC on Forms 4 and 5. Form 3 supplies initial ownership rather than a trade; Form 4 must be filed within two business days of the trade.
| Date | Insider | Role | Type | Security | Shares |
|---|---|---|---|---|---|
| 2026-07-29 | Kredo Russo Sharon |
SVP, Research & Discovery |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
18,000 |
| 2026-07-29 | ZWEIFACH SANFORD S |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
10,000 |
| 2026-07-29 | ZWEIFACH SANFORD S |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
7,500 |
| 2026-07-29 | Halevy Gilead |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
7,500 |
| 2026-07-29 | Hukkelhoven Mathias |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
10,000 |
| 2026-07-29 | Kredo Russo Sharon |
SVP, Research & Discovery |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
24,000 |
| 2026-07-29 | Levine Zurit |
SVP, Business Development |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
18,000 |
| 2026-07-29 | Ferre Pierre |
Chief Operating Officer |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
70,000 |
| 2026-07-29 | Silberman David |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
19,500 |
| 2026-07-29 | Silberman David |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
26,000 |
| 2026-07-29 | Livnat Savitzky Kinneret |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
10,000 |
| 2026-07-29 | Cohen-Dayag Anat |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
100,000 |
| 2026-07-29 | Ophir Eran |
Director, President and CEO |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
200,000 |
| 2026-07-29 | Hukkelhoven Mathias |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
7,500 |
| 2026-07-29 | Mahler Michelle |
Chief Medical Officer |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on September 30, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
13,500 |
| 2026-07-29 | Livnat Savitzky Kinneret |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
7,500 |
| 2026-07-29 | Halevy Gilead |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
10,000 |
| 2026-07-29 | Mahler Michelle |
Chief Medical Officer |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
18,000 |
| 2026-07-29 | Perry Eran |
Director |
Award↑
Filing footnotes — Ordinary Shares (Direct)
Represents a restricted stock unit ("RSU") award. The RSUs vest 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Ordinary Shares
|
7,500 |
| 2026-07-29 | Levine Zurit |
SVP, Business Development |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on September 30, 2027 and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
24,000 |
| 2026-07-29 | Perry Eran |
Director |
Award↑
Filing footnotes — Share Option (right to buy) (Direct)
This option vests 25% on October 1, 2027, and the remainder vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
10,000 |
| 2026-07-09 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
1,875 |
| 2026-07-09 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
1,875 |
| 2026-07-09 | Levine Zurit |
SVP, Business Development |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
1,875 |
| 2026-04-24 | Ophir Eran |
Director, President and CEO |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.20 to $3.205 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,000 |
| 2026-04-24 | Ophir Eran |
Director, President and CEO |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. |
Ordinary Shares
|
5,000 |
| 2026-04-24 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,000 |
| 2026-04-24 | Levine Zurit |
SVP, Business Development |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,000 |
| 2026-04-24 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
2,000 |
| 2026-04-24 | Ophir Eran |
Director, President and CEO |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
5,000 |
| 2026-04-14 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
2,000 |
| 2026-04-14 | Ophir Eran |
Director, President and CEO |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. |
Ordinary Shares
|
5,000 |
| 2026-04-14 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,000 |
| 2026-04-14 | Ophir Eran |
Director, President and CEO |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
5,000 |
| 2026-04-14 | Ophir Eran |
Director, President and CEO |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 26, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.90 to $2.91 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
5,000 |
| 2026-04-14 | Levine Zurit |
SVP, Business Development |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,000 |
| 2026-04-10 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
2,000 |
| 2026-04-10 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
1,125 |
| 2026-04-10 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
1,125 |
| 2026-04-10 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,000 |
| 2026-04-10 | Levine Zurit |
SVP, Business Development |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.50 to $2.60 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
Ordinary Shares
|
3,125 |
| 2026-04-08 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
4,375 |
| 2026-04-08 | Levine Zurit |
SVP, Business Development |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
5,375 |
| 2026-04-08 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on September 30, 2024 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
1,000 |
| 2026-04-08 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
1,000 |
| 2026-04-08 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
4,375 |
| 2026-04-07 | Levine Zurit |
SVP, Business Development |
Convert↓
Filing footnotes — Share Option (right to buy) (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. This option vested 25% on December 31, 2023 and the remainder vested or vests in 12 equal quarterly installments thereafter, subject to the Reporting Person's continued service to the Issuer. |
Share Option (right to buy)
|
2,500 |
| 2026-04-07 | Levine Zurit |
SVP, Business Development |
Sell↓
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,500 |
| 2026-04-07 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,500 |
| 2026-04-01 | Levine Zurit |
SVP, Business Development |
Convert↑
Filing footnotes — Ordinary Shares (Direct)
This transaction was made pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on December 23, 2025. |
Ordinary Shares
|
2,500 |